Zenas BioPharma, Inc. Common Stock ZBIO
i
Market dataready · fetched 2026-11-07T02:25:26.183Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T21:00:05.763782258Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-07T02:25:25.611413+00:00
Zenas BioPharma, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 20.54 | 296.9% | 36.0% | |||
| 25Δ | 23.02 | 235.5% | 27.2% | |||
| 30Δ | 24.96 | 190.3% | 20.3% | |||
| 35Δ | 30.87 | 85.7% | 12.8% | 26.00 | 176.5% | 17.6% |
| 40Δ | 29.85 | 82.2% | 9.9% | 27.02 | 163.2% | 14.9% |
| 45Δ | 29.24 | 82.7% | 8.9% | 28.03 | 150.0% | 12.3% |
| 50Δ | 28.62 | 83.2% | 8.0% | 29.05 | 136.8% | 9.6% |
| 55Δ | 28.00 | 83.7% | 7.0% | 30.07 | 124.4% | 7.0% |
| 60Δ | 27.39 | 84.2% | 6.0% | 31.14 | 123.8% | 6.1% |
| 65Δ | 26.77 | 84.7% | 5.1% | 32.22 | 123.2% | 5.1% |
| 70Δ | 26.15 | 85.3% | 4.1% | 33.29 | 122.7% | 4.1% |
| 75Δ | 25.54 | 85.8% | 3.1% | 34.36 | 122.1% | 3.1% |
| 80Δ | 24.89 | 85.8% | 2.2% | 36.19 | 126.9% | 2.3% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 20.54
- IV
- 296.9%
- B/E move
- 36.0%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 23.02
- IV
- 235.5%
- B/E move
- 27.2%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 24.96
- IV
- 190.3%
- B/E move
- 20.3%
35Δ
- Pseudo strike
- 30.87
- IV
- 85.7%
- B/E move
- 12.8%
- Pseudo strike
- 26.00
- IV
- 176.5%
- B/E move
- 17.6%
40Δ
- Pseudo strike
- 29.85
- IV
- 82.2%
- B/E move
- 9.9%
- Pseudo strike
- 27.02
- IV
- 163.2%
- B/E move
- 14.9%
45Δ
- Pseudo strike
- 29.24
- IV
- 82.7%
- B/E move
- 8.9%
- Pseudo strike
- 28.03
- IV
- 150.0%
- B/E move
- 12.3%
50Δ
- Pseudo strike
- 28.62
- IV
- 83.2%
- B/E move
- 8.0%
- Pseudo strike
- 29.05
- IV
- 136.8%
- B/E move
- 9.6%
55Δ
- Pseudo strike
- 28.00
- IV
- 83.7%
- B/E move
- 7.0%
- Pseudo strike
- 30.07
- IV
- 124.4%
- B/E move
- 7.0%
60Δ
- Pseudo strike
- 27.39
- IV
- 84.2%
- B/E move
- 6.0%
- Pseudo strike
- 31.14
- IV
- 123.8%
- B/E move
- 6.1%
65Δ
- Pseudo strike
- 26.77
- IV
- 84.7%
- B/E move
- 5.1%
- Pseudo strike
- 32.22
- IV
- 123.2%
- B/E move
- 5.1%
70Δ
- Pseudo strike
- 26.15
- IV
- 85.3%
- B/E move
- 4.1%
- Pseudo strike
- 33.29
- IV
- 122.7%
- B/E move
- 4.1%
75Δ
- Pseudo strike
- 25.54
- IV
- 85.8%
- B/E move
- 3.1%
- Pseudo strike
- 34.36
- IV
- 122.1%
- B/E move
- 3.1%
80Δ
- Pseudo strike
- 24.89
- IV
- 85.8%
- B/E move
- 2.2%
- Pseudo strike
- 36.19
- IV
- 126.9%
- B/E move
- 2.3%
Options history
Table
| Date | IV (%) |
|---|---|
| 88.30% | |
| 84.29% | |
| 86.62% | |
| 84.32% | |
| 87.68% | |
| 91.03% | |
| 92.49% | |
| 87.67% | |
| 90.97% | |
| 92.11% |
Biotechnology
ZLAB
Zai Lab Limited, a biopharmaceutical company, discovers, licenses, develops and markets therapies to treat cancer, autoimmune and infectious diseases in China. The company is…
More →ZNTL
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapies for the treatment of various cancers.…
More →ZURA
Zura Bio Limited (Ticker: ZURA) is a biotechnology firm dedicated to developing breakthrough therapies for autoimmune disorders and rare diseases. The company features a diverse…
More →ZVRA
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The…
More →ZYME
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops and markets biotherapeutic products for the treatment of cancer. The company is headquartered in…
More →AARD
Description unavailable
More →